Feasibility study of californium‐252 for the therapy of stage IV cervical cancer

Y. Maruyama, J. R. van Nagell, J. Yoneda, E. Donaldson, H. Gallion, P. Patel, R. J. Kryscio

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Twenty patients with Stage IVA and IVB cervic cancers were treated with Californium‐252 (Cf) neutron brachytherapy (NT) in a feasibility trial between 1976 and 1986. Eleven patients had Stage IVA disease; nine patients had Stage IVB disease. Patient compliance with therapy was poor in four of nine patients with Stage IVB disease, and the 50% survival time was 6 months. In Stage IVA disease there were 18% 3‐year survivals. For those that failed, the 50% survival time was 7.5 months. Because of the frequency of disseminated metastases, effective adjuvant therapy needs to be developed to use after the tumor debulking therapy, especially for Stage IVB disease. A single early Cf‐NT implant followed by 6000 cGy of whole‐pelvis fractionated radiation would accomplish this adequately for local tumor control and palliation.

Original languageEnglish
Pages (from-to)2448-2452
Number of pages5
Issue number12
StatePublished - Jun 15 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Feasibility study of californium‐252 for the therapy of stage IV cervical cancer'. Together they form a unique fingerprint.

Cite this